EIGR

Peginterferon Lambda (Lambda)

Hepatitis Delta Virus Infection

Phase 3

Exp Date

TBA

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Peginterferon Lambda (Lambda) for Hepatitis Delta Virus Infection

  • ClinicalTrials.gov (NCT03600714) Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 LIFT (combo with lonafarnib) end-of-study data expected at AASLD 2020 Agreement with FDA and EMA on single, Phase 3 Lambda monotherapy study design


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBA


PRIOR DATA

PRESS RELEASES


MECHANISM OF ACTION

  • Lonafarnib is a well-characterized, late-stage, oral inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation, a vital process in the life cycle of HDV.  Blocking prenylation of the large delta hepatitis antigen (LDHAg) reduces HDV replication.

Updated by JM 

#EIGR, EIGER, HDV, Hepatitis Delta Virus Infection, Peginterferon Lambda (Lambda)

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

EIGR - Eiger BioPharmaceutical...

Summary: Zokinvy increases survival by 2.5 years in children and young adults with Progeria Rare Pediatric Disease Priority Review Voucher issued to Eiger from FDA Eiger to host an investor call, Nove...

EIGR - Announces Results of In...

#EIGR "announced results of an investigator sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.  The primary endpoint was duration of viral shed...

EIGR - Eiger Announces Peginte...

Summary: Week 48 (24 Weeks Post-Treatment) Results Presented 23% of Patients BLOQ or Undetectable HDV RNA at Week 48 55% of Patients Improved in Histology Activity Index (HAI) at Week 48 #EIGR "today...

EIGR - Eiger BioPharmaceutica...

Summary: Lambda significantly accelerated viral decline Viral clearance highly correlated with baseline viral loads- All Lambda-treated patients were below the infectivity threshold by Day 7 #EIGR "...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon